Article
Immunology
Kissy Guevara-Hoyer, Jesus Fuentes-Antras, Eduardo de la Fuente-munoz, Miguel Fernandez-Arquero, Fernando Solano, Pedro Perez-Segura, Esmeralda Neves, Alberto Ocana, Rebeca Perez de Diego, Silvia Sanchez-Ramon
Summary: This study aims to explore the shared genomic basis between common variable immunodeficiency (CVID) and non-Hodgkin's lymphoma (NHL), in order to better understand the immunodeficiency phenotype of CVID in NHL. The study found that NHL samples harbored genetic variants associated with CVID, indicating the existence of shared pathological mechanisms and signaling pathways.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Maria Kallergi, Alexandros Georgakopoulos, Vassiliki Lyra, Sofia Chatziioannou
Summary: This study investigated the value of tumor measurements in predicting treatment outcomes for Hodgkin's and Non-Hodgkin's lymphomas. Results showed that while SUVmax was the strongest prognostic indicator, automated metabolic tumor volume measurements and expert's metabolic maximum diameter measurements also provided valuable insights. Anatomic tumor measurements had poor prognostic value. The study suggests a paradigm shift towards identifying robust prognostic markers in PET/CT with the use of radiomics.
Article
Medicine, General & Internal
Jiamei Wu, Yin Zhou, Qingshu Li, Jing Zhang, Yun Mao
Summary: PBNHL is a rare disease with difficult preoperative diagnosis, so it should be considered when encountering cases with Epstein-Barr virus infection and typical imaging findings.
Article
Multidisciplinary Sciences
De Matteis Sara, Cosetta Minelli, Giorgio Broccia, Paolo Vineis, Pierluigi Cocco
Summary: This ecological study investigates the link between COVID-19 incidence, socio-economic covariates, and NHL incidence. The results show that COVID-19 cumulative incidence is positively associated with past NHL incidence, socioeconomic deprivation, and proportion of elderly residents, while negatively associated with urban residency. Further investigation is needed to explore shared susceptibility factors among the plausible underlying mechanisms.
Article
Multidisciplinary Sciences
Giorgio Broccia, Jonathan Carter, Cansu Ozsin-Ozler, Federico Meloni, Sara De Matteis, Pierluigi Cocco
Summary: The incidence of non-Hodgkin's lymphoma (NHL) in Sardinia showed an upward trend from 1974 to 2003, prompting further research on the genetic and environmental factors in the high-risk areas.
Article
Oncology
Lan-Hsi Lin, Mohammad Ghasemi, Sarah M. Burke, Cory K. Mavis, Jenna R. Nichols, Pallawi Torka, Donald E. Mager, Francisco J. Hernandez-Ilizaliturri, Andrew K. L. Goey
Summary: A population-based pharmacokinetic/pharmacodynamic (PK/PD) model of carfilzomib was successfully developed through a clinical trial. The model can be used to study the drug metabolism and effects in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who receive carfilzomib in combination with R-ICE regimen. The study results show that the model estimates are accurate, but further research is needed to identify sources of variability in response to carfilzomib treatment in combination with R-ICE.
Article
Oncology
Weifeng Wang, Zhuo Zhang, Xiaocong Deng, Anqi Gu, Xianzhao Chen, Yizheng Cai, Yuting Zhao
Summary: In this case report, a 57-year-old male patient with diffuse large B-cell lymphoma was successfully treated with radiation therapy and medication, achieving complete remission.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Kathryn Lurain, Ramya Ramaswami, Ralph Mangusan, Anaida Widell, Irene Ekwede, Jomy George, Richard Ambinder, Martin Cheever, James L. Gulley, Priscila H. Goncalves, Hao-Wei Wang, Thomas S. Uldrick, Robert Yarchoan
Summary: The most common malignancy among people living with HIV in the USA is Non-Hodgkin's lymphoma (NHL). The study found that using pembrolizumab with or without pomalidomide to treat HIV-associated NHL elicited responses in several subtypes of HIV-associated NHL. This approach is worth further study in individuals living with HIV and NHL.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Richard A. Newcomb, P. Connor Johnson, Daniel Yang, Katherine Holmbeck, Joanna Choe, Anisa Nabily, Porsha Lark, Tejaswini Dhawale, Hermioni L. Amonoo, Areej El-Jawahri
Summary: Patients with indolent non-Hodgkin's lymphomas (iNHL) report significant psychological distress, a diversity of coping strategies, and complex cognitive understanding of their prognosis. Interventions that address prognostic uncertainty and promote positive emotional coping with prognosis may ameliorate psychological distress in this population.
Article
Hematology
Kwee Yong, William Wilson, Ruth M. de Tute, Marquita Camilleri, Karthik Ramasamy, Matthew Streetly, Jonathan Sive, Ceri A. Bygrave, Reuben Benjamin, Michael Chapman, Selina J. Chavda, Elizabeth H. Phillips, Maria del Mar Cuadrado, Gavin Pang, Richard Jenner, Tushhar Dadaga, Sumaiya Kamora, James Cavenagh, Laura Clifton-Hadley, Roger G. Owen, Rakesh Popat
Summary: This study aimed to evaluate the efficacy difference between a CAR-T decision-making strategy that does not require autologous HSCT and standard treatment. The results showed that the CAR-T decision-making strategy was not inferior in terms of progression-free survival compared to standard treatment, but further research is still needed.
LANCET HAEMATOLOGY
(2023)
Article
Oncology
Jingwen Li, Fei Peng, He Huang, Zhen Cai
Summary: The relative and cumulative risk of developing second primary malignancies significantly increased in patients diagnosed with non-Hodgkin's lymphoma in recent years. The risk was associated with certain clinical and demographic variables.
AMERICAN JOURNAL OF CANCER RESEARCH
(2022)
Article
Pharmacology & Pharmacy
Jie Wang, Ting Liu
Summary: This study evaluated the efficacy of bortezomib-based chemotherapy in different subtypes of NHL. The results showed that patients with p65-positive expression had a higher complete remission rate, and the activation of NF-kappa B p65 was associated with a higher remission rate, while the activation of RelB was associated with a higher risk of inefficacy. Monitoring the activation of NF-kappa B and RelB can help in selecting bortezomib therapy.
INTERNATIONAL JOURNAL OF PHARMACOLOGY
(2022)
Article
Oncology
Cristina Gasparetto, Gary J. Schiller, Sascha A. Tuchman, Natalie S. Callander, Muhamed Baljevic, Suzanne Lentzsch, Adriana C. Rossi, Rami Kotb, Darrell White, Nizar J. Bahlis, Christine Chen, Heather J. Sutherland, Sumit Madan, Richard LeBlanc, Michael Sebag, Christopher P. Venner, William Bensinger, Noa Biran, Sonia Ammu, Osnat Ben-Shahar, Andrew DeCastro, Dane Van Domelen, Tianjun Zhou, Chris Zhang, Ohad S. Bentur, Jatin Shah, Sharon Shacham, Michael Kauffman, Brea Lipe
Summary: The study evaluated the safety and efficacy of the XKd regimen in patients with relapsed refractory MM, and found it to be highly effective and well-tolerated, supporting further investigation of this regimen in MM patients.
BRITISH JOURNAL OF CANCER
(2022)
Article
Oncology
Luciano J. Costa, Saurabh Chhabra, Eva Medvedova, Bhagirathbhai R. Dholaria, Timothy M. Schmidt, Kelly N. Godby, Rebecca Silbermann, Binod Dhaka, Susan Bal, Smith Gid, Anita D'Souza, Aric Hall, Pamela Hardwick, James Omel, Robert F. Cornell, Parameswaran Had, Natalie S. Callander
Summary: Dara-KRd, AHCT, and MRD response-adapted consolidation lead to a high rate of MRD negativity in NDMM patients. This strategy creates the opportunity of MRD surveillance as an alternative to indefinite maintenance for patients with 0 or 1 HRCA.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Multidisciplinary Sciences
Lenka Besse, Marianne Kraus, Andrej Besse, Christoph Driessen, Ignazio Tarantino
Summary: Chemotherapy resistance is a major problem in NSCLC treatment, and new strategies are needed. The combination of BTZ and NFV induces proteotoxicity and shows efficacy in NSCLC. CFZ, a second-generation proteasome inhibitor, combined with NFV is superior to BTZ + NFV and induces proteotoxicity and endoplasmic reticulum stress in NSCLC cells.
SCIENTIFIC REPORTS
(2023)
Article
Hematology
Alex F. Herrera, Andre Goy, Amitkumar Mehta, Radhakrishnan Ramchandren, John M. Pagel, Jakub Svoboda, Shanhong Guan, John S. Hill, Kevin Kwei, Emily A. Liu, Tycel Phillips
AMERICAN JOURNAL OF HEMATOLOGY
(2020)
Article
Medicine, General & Internal
Michael Wang, Javier Munoz, Andre Goy, Frederick L. Locke, Caron A. Jacobson, Brian T. Hill, John M. Timmerman, Houston Holmes, Samantha Jaglowski, Ian W. Flinn, Peter A. McSweeney, David B. Miklos, John M. Pagel, Marie-Jose Kersten, Noel Milpied, Henry Fung, Max S. Topp, Roch Houot, Amer Beitinjaneh, Weimin Peng, Lianqing Zheng, John M. Rossi, Rajul K. Jain, Arati V. Rao, Patrick M. Reagan
NEW ENGLAND JOURNAL OF MEDICINE
(2020)
Article
Multidisciplinary Sciences
Andrew Ip, Donald A. Berry, Eric Hansen, Andre H. Goy, Andrew L. Pecora, Brittany A. Sinclaire, Urszula Bednarz, Michael Marafelias, Scott M. Berry, Nicholas S. Berry, Shivam Mathura, Ihor S. Sawczuk, Noa Biran, Ronaldo C. Go, Steven Sperber, Julia A. Piwoz, Bindu Balani, Cristina Cicogna, Rani Sebti, Jason Zuckerman, Keith M. Rose, Lisa Tank, Laurie Jacobs, Jason Korcak, Sarah L. Timmapuri, Joseph P. Underwood, Gregory Sugalski, Carol Barsky, Daniel W. Varga, Arif Asif, Joseph C. Landolfi, Stuart L. Goldberg
Review
Hematology
Andre Goy
Summary: Treatment outcomes for MCL have improved, but high-risk patients still face poor prognosis. Studies indicate that high-risk molecular features are driving a new treatment paradigm, with advancements in novel therapies and diagnostics potentially enhancing outcomes for MCL patients.
EXPERT REVIEW OF HEMATOLOGY
(2021)
Article
Oncology
Maher Albitar, Hong Zhang, Andre Goy, Zijun Y. Xu-Monette, Govind Bhagat, Carlo Visco, Alexandar Tzankov, Xiaosheng Fang, Feng Zhu, Karen Dybkaer, April Chiu, Wayne Tam, Youli Zu, Eric D. Hsi, Fredrick B. Hagemeister, Jooryung Huh, Maurilio Ponzoni, Andres J. M. Ferreri, Michael B. Moller, Benjamin M. Parsons, J. Han van Krieken, Miguel A. Piris, Jane N. Winter, Yong Li, Bing Xu, Ken H. Young
Summary: Multiple studies have shown that DLBCL can be divided into distinct subgroups based on biology, but these subgroups often overlap clinically. In this study, a machine learning approach was used to stratify DLBCL patients into four survival subgroups based on gene expression data. The model accurately predicted the subgroups and their prognosis, and it was validated using independent patient groups. This stratification strategy can help identify patients who may not respond well to standard therapy and could benefit from alternative treatments or clinical trials.
BLOOD CANCER JOURNAL
(2022)
Article
Oncology
Michael Wang, Javier Munoz, Andre Goy, Frederick L. Locke, Caron A. Jacobson, Brian T. Hill, John M. Timmerman, Houston Holmes, Samantha Jaglowski, Ian W. Flinn, Peter A. McSweeney, David B. Miklos, John M. Pagel, Marie Jose Kersten, Krimo Bouabdallah, Rashmi Khanal, Max S. Topp, Roch Houot, Amer Beitinjaneh, Weimin Peng, Xiang Fang, Rhine R. Shen, Rubina Siddiqi, Ioana Kloos, Patrick M. Reagan
Summary: Brexucabtagene autoleucel (KTE-X19) autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has shown durable long-term responses with manageable safety in patients with relapsed/refractory mantle cell lymphoma (MCL) and may benefit those with high-risk characteristics.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Hematology
Michael R. Cook, C. Scott Dorris, Kepher H. Makambi, Yutong Luo, Pashna N. Munshi, Michelle Donato, Scott Rowley, Ayman Saad, Andre Goy, Kieron Dunleavy, Alaa Ali
Summary: Relapsed/refractory primary central nervous system lymphoma (PCNSL) and secondary central nervous system lymphoma (SCNSL) have limited treatment options and poor prognosis. This study conducted a systematic review and meta-analysis of CAR T-cell therapy in PCNSL and SCNSL. The results showed that CAR T-cell therapy had acceptable toxicity and promising efficacy in both PCNSL and SCNSL patients.
Article
Oncology
Kristie A. Blum, Jeffrey G. Supko, Michael B. Maris, Ian W. Flinn, Andre Goy, Anas Younes, Suresh Bobba, Adrian M. Senderowicz, Sergey Efuni, Ronda Rippley, Gozde Colak, Patrick Trojer, Jeremy S. Abramson
Summary: The study demonstrates that Pelabresib is a safe and effective BET inhibitor that can suppress target genes and potentially modify disease pathways. This research provides a foundation for further investigation of Pelabresib in patients with myelofibrosis.
CANCER RESEARCH COMMUNICATIONS
(2022)
Meeting Abstract
Oncology
Anthony Mato, Lindsey Roeker, Toby Eyre, Chaitra Ujjani, Nicole Lamanna, Brian Hill, Paul Barr, Erick Lansigan, Bruce D. Cheson, Maryam Yazdy, John Allan, Joanna Rhodes, Kaitlin Kennard, Steven Schuster, Chadi Nabhan, Alan Skarbnik, Andre Goy, Colleen Dorsey, Julie Goodfriend, Catherine Coombs, Hande H. Tuncer, John Pagel, Ryan Jacobs, Amy Kirkwood, Allison Winter, Anna Schuh, Neil Bailey, Andrea Sitlinger, Mazyar Shadman, Christopher Fox, Danielle Brander
LEUKEMIA & LYMPHOMA
(2020)
Meeting Abstract
Oncology
Lindsey Roeker, Danielle Brander, Catherine Coombs, Steven Schuster, John Allan, Brian Hill, Erick Lansigan, Bruce D. Cheson, Maryam Yazdy, Nicole Lamanna, Paul Barr, Alan Skarbnik, Chaitra Ujjani, Mazyar Shadman, Joanna Rhodes, John M. Pagel, Ryan Jacobs, Andre Goy, Nirav Shah, Andrew Zelenetz, Anna Schuh, Toby Eyre, Christopher Fox, Anthony Mato
LEUKEMIA & LYMPHOMA
(2020)
Meeting Abstract
Oncology
Chaitra Ujjani, Anthony Mato, Brian Hill, John Allan, Erick Lansigan, Alan Skarbnik, Ryan Jacobs, Meghan Thompson, Jakub Svoboda, Hande H. Tuncer, John Pagel, Danielle Brander, Bruce D. Cheson, Paul Barr, Clive S. Zent, Joanna Rhodes, Lindsey Roeker, Jeffrey Pu, Sasanka Handunnetti, Chadi Nabhan, Nirav Shah, Andre Goy, Peter Pickens, Steven Schuster, Nicole Lamanna, Alison Sehgal, Constantine Tam, Mazyar Shadman
LEUKEMIA & LYMPHOMA
(2020)
Meeting Abstract
Biotechnology & Applied Microbiology
Michael Wang, Javier Munoz, Andre Goy, Frederick L. Locke, Caron A. Jacobson, Brian T. Hill, John M. Timmerman, Houston Holmes, Samantha Jaglowski, Ian W. Flinn, Peter A. McSweeney, David B. Miklos, John M. Pagel, Marie Jose Kersten, Weimin Peng, Lianqing Zheng, John M. Rossi, Rajul K. Jain, Arati V. Rao, Patrick M. Reagan
Meeting Abstract
Hematology
M. Wang, J. Munoz, A. Goy, F. Locke, C. Jacobson, B. Hill, J. Timmerman, H. Holmes, S. Jaglowski, I. Flinn, P. McSweeney, D. Miklos, J. Pagel, M. J. Kersten
BRITISH JOURNAL OF HAEMATOLOGY
(2020)
Meeting Abstract
Hematology
S. S. Neelapu, A. Ghobadi, C. A. Jacobson, D. B. Miklos, L. J. Lekakis, O. O. Oluwole, Y. Lin, I. Braunschweig, B. T. Hill, J. M. Timmerman, A. Deol, P. M. Reagan, P. Stiff, I. W. Flinn, U. Farooq, A. Goy, P. A. McSweeney, J. Munoz, T. Siddiqi, J. C. Chavez, A. F. Herrera, A. Xue, Y. Jiang, A. Bot, J. M. Rossi, J. J. Kim, W. Y. Go, F. L. Locke
BRITISH JOURNAL OF HAEMATOLOGY
(2019)
Meeting Abstract
Hematology
Michael Wang, Javier Munoz, Andre Goy, Frederick L. Locke, Caron A. Jacobson, Brian T. Hill, John M. Timmerman, Houston Holmes, Samantha Jaglowski, Ian W. Flinn, Peter A. McSweeney, David B. Miklos, John M. Pagel, Marie Jose Kersten, Weimin Peng, Lianqing Zheng, John M. Rossi, Rajul K. Jain, Arati V. Rao, Patrick M. Reagan
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
(2020)